Holen Sie sich die Stockscreener-App
13.94
2.95%
0.40
Handel nachbörslich:
13.67
-0.27
-1.94%
Schlusskurs vom Vortag:
$13.54
Offen:
$13.5
24-Stunden-Volumen:
293.56K
Relative Volume:
1.62
Marktkapitalisierung:
$527.86M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-63.78M
KGV:
-5.2015
EPS:
-2.68
Netto-Cashflow:
$-53.91M
1W Leistung:
+1.16%
1M Leistung:
+20.17%
6M Leistung:
+23.69%
1J Leistung:
-23.70%
1-Tages-Spanne:
$13.50
$14.08
1-Wochen-Bereich:
$13.47
$14.45
52-Wochen-Spanne:
$7.575
$19.77
Celcuity Inc Stock (CELC) Company Profile
Firmenname
Celcuity Inc
Sektor
Branche
Telefon
763-392-0767
Adresse
16305 36TH AVENUE N, MINNEAPOLIS, MN
Vergleichen Sie CELC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
13.94 | 521.80M | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-01 | Fortgesetzt | Stifel | Buy |
| 2024-07-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-02-22 | Eingeleitet | Stifel | Buy |
| 2023-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-09-07 | Eingeleitet | Jefferies | Buy |
| 2021-07-29 | Eingeleitet | Cowen | Outperform |
| 2021-07-27 | Eingeleitet | Needham | Buy |
| 2021-01-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-11 | Fortgesetzt | Craig Hallum | Buy |
| 2018-11-20 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Celcuity Inc Aktie (CELC) Neueste Nachrichten
Is Celcuity Inc. a good long term investmentFree Stock Market Real-Time Monitoring - jammulinksnews.com
What analysts say about Celcuity Inc. stockBreakthrough investment results - jammulinksnews.com
Celcuity Inc. Stock Analysis and ForecastSuperior profit margins - jammulinksnews.com
What drives Celcuity Inc. stock priceSuperior stock growth - jammulinksnews.com
why celcuity inc. stock attracts strong analyst attentionTop Rated Trade Entries - Newser
What makes Celcuity Inc. stock price move sharplyFree Elite Traders Group - Newser
How Celcuity Inc. stock performs during market volatilityBreakout Momentum Alerts - Newser
Why Celcuity Inc. stock attracts strong analyst attentionProven High Yield Signals - Newser
Celcuity receives U.S. patent for gedatolisib dosing regimen - Investing.com Australia
How To Trade (CELC) - news.stocktradersdaily.com
Celcuity Soars 17.16% on New Patent for Breast Cancer Drug - AInvest
Celcuity Receives New Patent for Gedatolisib - MarketScreener
Celcuity receives U.S. patent for gedatolisib dosing regimen By Investing.com - Investing.com South Africa
Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042 - The Manila Times
Celcuity, Inc. (NASDAQ:CELC) Receives $28.40 Average Target Price from Analysts - Defense World
Celcuity projects $2B revenue potential for gedatolisib in second-line breast cancer market - MSN
Celcuity(CELC) Shares Soar 4.70% on Phase 2 Trial Success - AInvest
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention - PentictonNow
Learn to Evaluate (CELC) using the Charts - news.stocktradersdaily.com
Stifel Initiates Celcuity(CELC.US) With Buy Rating, Announces Target Price $30 - 富途牛牛
Celcuity (NASDAQ:CELC) Given Buy Rating at Needham & Company LLC - Defense World
Celcuity Announces Promising Phase 1 Gedatolisib Results - TipRanks
Celcuity reports positive early data for gedatolisib in cancer trials By Investing.com - Investing.com UK
New Clinical Data: Celcuity's Cancer Drug Achieves Breakthrough Results in Dual Phase Studies - Stock Titan
Rhumbline Advisers Has $427,000 Stock Position in Celcuity, Inc. (NASDAQ:CELC) - Defense World
Analysts Set Celcuity Inc. (NASDAQ:CELC) Price Target at $30.80 - Defense World
Wealth Enhancement Advisory Services LLC Grows Stock Holdings in Celcuity Inc. (NASDAQ:CELC) - Defense World
Stocks in play: Roots Corp. - The Globe and Mail
(CELC) Trading Advice - news.stocktradersdaily.com
Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - Revista ADVFN
Cisco Powers AI-Ready Data Centers, From Hyperscale to Enterprise - The Globe and Mail
Millennium Management LLC Has $519,000 Stock Holdings in Celcuity Inc. (NASDAQ:CELC) - Defense World
Two Sigma Investments LP Has $679,000 Stock Holdings in Celcuity Inc. (NASDAQ:CELC) - Defense World
Nuveen Asset Management LLC Grows Position in Celcuity Inc. (NASDAQ:CELC) - Defense World
Ballard announces 1.5 MW fuel cell engine order for Sierra Northern Railway - The Globe and Mail
Citadel Advisors LLC Buys New Stake in HUHUTECH International Group Inc. (NASDAQ:HUHU) - Defense World
Two Sigma Advisers LP Decreases Stock Position in Celcuity Inc. (NASDAQ:CELC) - Defense World
Celcuity Inc. (NASDAQ:CELC) Shares Sold by BNP Paribas Financial Markets - Defense World
Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update - ACCESS Newswire
BMO Lowers Fees on Asset Allocation ETFs to Deliver Greater Value to Investors - The Globe and Mail
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $258,000 Holdings in Celcuity Inc. (NASDAQ:CELC) - Defense World
Deutsche Bank AG Purchases 9,174 Shares of Celcuity Inc. (NASDAQ:CELC) - Defense World
Finanzdaten der Celcuity Inc-Aktie (CELC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):